Press Releases

MYOS RENS Technology Announces Upcoming Presentation of Results from a Kansas State University Study Evaluating the Impact of Fortetropin® on Canine Muscle Loss after Surgery, at a Major Veterinary Conference, January 20, 2019

Download PDF

Results Relevant to Company's Veterinary and Human Nutrition Business

CEDAR KNOLLS, N.J., Jan. 8, 2019 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announces the presentation of study results that evaluated the impact of Fortetropin® on canine muscle loss following surgery, on January 20, 2019 at the North American Veterinary Community (NAVC) / VMX Conference (  in Orlando, Florida.  Kenneth R. Harkin DVM, DACVIM (SAIM), Professor and Section Head, College of Veterinary Medicine, Kansas State University and the principal investigator of the study, will present the results as part of an oral presentation titled, "The Impact of Fortetropin® Supplementation on Dogs Recovering from Tibial-Plateau Leveling Osteotomy (TPLO) Surgery" at 3:15 PM in the Discovery Theater at the VMX Conference.

(PRNewsfoto/MYOS RENS Technology)

The randomized, double-blind, placebo-controlled study evaluated the impact of Fortetropin on attenuating muscle atrophy following a common surgical procedure known as tibial-plateau leveling osteotomy (TPLO) in 100 dogs at Kansas State University.  TPLO is performed by veterinary surgeons to repair ruptures of the cranial cruciate ligament (CCL), a canine ligament that is analogous to the anterior cruciate ligament (ACL) in humans.  In the weeks that follow TPLO surgery, the immobilized operated limb frequently shows significant muscle loss due to muscle disuse atrophy.  The objective of the study was to determine whether Fortetropin could reduce this muscle atrophy with respect to a macronutrient-matched placebo. 

Joseph Mannello, CEO, MYOS, commented, "The results of this Kansas State study are not only relevant to the company's veterinary business, which was established in 2018, but are also relevant to MYOS' human muscle nutrition business, with a particular focus on recovery and rehabilitation."

The Northern American Veterinary Community (NAVC) Conference / VMX is one of the leading veterinary conferences in the world.  The event is expected to attract >17,000 veterinary professionals from around the world in addition to >700 corporate exhibitors.  MYOS Canine Muscle Formula (a Fortetropin product) will be available at the conference, and is currently available at   

About MYOS RENS Technology Inc. 
MYOS RENS Technology Inc. (MYOS), "The Muscle Company®", is a Cedar Knolls, NJ-based bionutrition company that develops and markets products that improve muscle health and performance. MYOS is the owner of Fortetropin®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin has been clinically shown to increase muscle size and lean body mass in conjunction with resistance training. MYOS believes Fortetropin has the potential to redefine existing standards of physical health and wellness. For more information, please visit

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful results of strategic initiatives, the successful launch of our products, including Qurr®, Yolked®, MYOS Enteral Nutrition Formula™ and MYOS Canine Muscle Formula™ products, the success of our research and development, the results of the clinical evaluation of Fortetropin® and its effects, the ability to enter into new partnership opportunities and the success of our existing partnerships, the ability to generate the forecasted revenue stream and cash flow from sales of our products, the ability to continue increasing our revenue and gross profit margins, the ability to achieve a sustainable, profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, the continued listing of our securities on the Nasdaq Stock Market, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our filings with  the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700

Cision View original content to download multimedia: